Industry news
Millendo Therapeutics acquires Alizé Pharma SAS and with it livoletide, a drug that is in Phase II to treat Prader Willi Syndrome.
Millendo Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases, announced that it has acquired Alizé Pharma SAS in a stock-based transaction and with it livoletide that has demonstrated encouraging efficacy for treatent of Prader Willi Syndrome (PWS).The company will operate as Millendo Therapeutics, Inc. in the United States and as Millendo Therapeutics SAS in France.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
